Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn’s disease of inflammatory type

0 / 5 (0 votos)

Journal of Gastroenterology

Fecha de publicación: 22 september 2018


Autores: Nagata, Y., Esaki, M., Moriyama, T. et al.

Background: Anti-tumor necrosis factor (TNF) therapy induces and maintains clinical remission in patients with Crohn’s disease (CD). However, the effect of anti-TNF therapy on the natural course of CD remains controversial. We aimed to investigate the effect of anti-TNF therapy on the initial intestinal surgery for CD.

Seguir leyendo